Reduction of steroid-induced intraocular pressure elevation in sheep by tissue plasminogen activator

Investigative Ophthalmology and Visual Science

Volumn 54, Issue 13, 2013, Pages 7903-7909

  Gerometta, Rosana ^a,b   Kumar, Sandeep ^c,d   Shah, Shaily ^d   Alvarez, Larry ^b   Candia, Oscar ^b   Danias, John ^c,d  

^a UNIVERSIDAD NACIONAL DEL NORDESTE   (Argentina)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c SUNY Downstate Medical Center   (United States)

^d SUNY DOWNSTATE MEDICAL CENTER   (United States)

Author keywords

Extracellular matrix; Intraocular pressure; Matrix metalloproteinase; Tissue plasminogen activator; Trabecular meshwork

Indexed keywords

ALTEPLASE; ARGININE; COLLAGENASE 3; GELATINASE A; GELATINASE B; INTERSTITIAL COLLAGENASE; PLASMINOGEN ACTIVATOR INHIBITOR 1; PREDNISOLONE; PREDNISOLONE ACETATE; TISSUE PLASMINOGEN ACTIVATOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; NONHUMAN; OCULOPLETHYSMOGRAPHY; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SHEEP; TRABECULAR MESHWORK;

EXTRACELLULAR MATRIX; INTRAOCULAR PRESSURE; MATRIX METALLOPROTEINASE; TISSUE PLASMINOGEN ACTIVATOR; TRABECULAR MESHWORK;

ANIMALS; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FIBRINOLYTIC AGENTS; GENE EXPRESSION REGULATION; INTRAOCULAR PRESSURE; INTRAVITREAL INJECTIONS; MATRIX METALLOPROTEINASES; OCULAR HYPERTENSION; PREDNISOLONE; REAL-TIME POLYMERASE CHAIN REACTION; RNA; SHEEP; TISSUE PLASMINOGEN ACTIVATOR; TRABECULAR MESHWORK;

EID: 84889566593     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.13-12801     Document Type: Article

References (55)

1. Lijnen HR, Collen D. Mechanisms of physiological fibrinolysis. Baillieres Clin Haematol. 1995;8:277-290.
2. Matrisian LM. Metalloproteinases and their inhibitors in matrix remodeling. Trends Genet. 1990;6:121-125.
3. Murphy G, Atkinson S, Ward R, Gavrilovic J, Reynolds JJ. The role of plasminogen activators in the regulation of connective tissue metalloproteinases. Ann N Y Acad Sci. 1992;667:1-12.
4. Bradley JM, Vranka J, Colvis CM, et al. Effect of matrix metalloproteinases activity on outflow in perfused human organ culture. Invest Ophthalmol Vis Sci. 1998;39:2649-2658.
5. Keller KE, Aga M, Bradley JM, Kelley MJ, Acott TS. Extracellular matrix turnover and outflow resistance. Exp Eye Res. 2009;88: 676-682.
6. Park JK, Tripathi RC, Tripathi BJ, Barlow GH. Tissue plasminogen activator in the trabecular endothelium. Invest Ophthalmol Vis Sci. 1987;28:1341-1345.
7. Shuman MA, Polansky JR, Merkel C, Alvarado JA. Tissue plasminogen activator in cultured human trabecular meshwork cells: predominance of enzyme over plasminogen activator inhibitor. Invest Ophthalmol Vis Sci. 1988;29:401-405.
8. Tripathi RC, Park JK, Tripathi BJ, Millard CB. Tissue plasminogen activator in human aqueous humor and its possible therapeutic significance. Am J Ophthalmol. 1988; 106:719-722.
9. Francois J. Corticosteroid glaucoma. Ophthalmologica. 1984; 188:76-81.
10. Snyder RW, Stamer WD, Kramer TR, Seftor RE. Corticosteroid treatment and trabecular meshwork proteases in cell and organ culture supernatants. Exp Eye Res. 1993;57:461-468.
11. Seftor RE, Stamer WD, Seftor EA, Snyder RW. Dexamethasone decreases tissue plasminogen activator activity in trabecular meshwork organ and cell cultures. J Glaucoma. 1994;3:323-328.
12. Rhen T, Cidlowski JA. Antiinflammatory action of glucocorticoids-new mechanisms for old drugs. N Engl J Med. 2005; 353:1711-1723.
13. Spies CM, Strehl C, van der Goes MC, Bijlsma JW, Buttgereit F. Glucocorticoids. Best Pract Res Clin Rheumatol. 2011;25: 891-900.
14. LeHoang P. The gold standard of noninfectious uveitis: corticosteroids. Dev Ophthalmol. 2012;51:7-28.
15. Oliver A, Ciulla TA. Corticosteroids as antiangiogenic agents. Ophthalmol Clin North Am. 2006;19:345-351.
16. Gillies MC, Kuzniarz M, Craig J, Ball M, Luo W, Simpson JM. Intravitreal triamcinolone-induced elevated intraocular pressure is associated with the development of posterior subcapsular cataract. Ophthalmology. 2005;112:139-143.
17. Gordon DM, McLean J, Koteen H, et al. The use of ACTH and cortisone in ophthalmology. Am J Ophthalmol. 1951;34: 1675-1686.
18. Jones R III, Rhee DJ. Corticosteroid-induced ocular hypertension and glaucoma: a brief review and update of the literature. Curr Opin Ophthalmol. 2006;17:163-167.
19. Kersey JP, Broadway DC. Corticosteroid-induced glaucoma: a review of the literature. Eye (Lond). 2006;20:407-416.
20. Gerometta R, Podos SM, Danias J, Candia OA. Steroid-induced ocular hypertension in normal sheep. Invest Ophthalmol Vis Sci. 2009;50:669-673.
21. Danias J, Gerometta R, Ge Y, et al. Gene expression changes in steroid-induced IOP elevation in bovine trabecular meshwork. Invest Ophthalmol Vis Sci. 2011;52:8636-8645.
22. Seeds NW, Basham ME, Haffke SP. Neuronal migration is retarded in mice lacking the tissue plasminogen activator gene. Proc Natl Acad Sci U S A. 1999;96:14118-14123.
23. Dan J, Belyea D, Gertner G, Leshem I, Lusky M, Miskin R. Plasminogen activator inhibitor-1 in the aqueous humor of patients with and without glaucoma. Arch Ophthalmol. 2005; 123:220-224.
24. Masos T, Dan JA, Miskin R. Plasminogen activator inhibitor-1 mRNA is localized in the ciliary epithelium of the rodent eye. Invest Ophthalmol Vis Sci. 2000;41:1006-1011.
25. Fuchshofer R, Welge-Lussen U, Lutjen-Drecoll E. The effect of TGF-beta2 on human trabecular meshwork extracellular proteolytic system. Exp Eye Res. 2003;77:757-765.
26. Fleenor DL, Shepard AR, Hellberg PE, Jacobson N, Pang IH, Clark AF. TGFbeta2-induced changes in human trabecular meshwork: implications for intraocular pressure. Invest Ophthalmol Vis Sci. 2006;47:226-234.
27. Wedrich A, Menapace R, Ries E, Polzer I. Intracameral tissue plasminogen activator to treat severe fibrinous effusion after cataract surgery. J Cataract Refract Surg. 1997;23:873-877.
28. Wu TT, Wang HH. Intracameral recombinant tissue plasminogen activator for the treatment of severe fibrin reaction in endophthalmitis. Eye (Lond). 2009;23:101-107.
29. Erol N, Ozer A, Topbas S, Yildirim N, Yurdakul S. Treatment of intracameral fibrinous membranes with tissue plasminogen activator. Ophthalmic Surg Lasers Imaging. 2003;34:451-456.
30. Ozveren F, Eltutar K. Therapeutic application of tissue plasminogen activator for fibrin reaction after cataract surgery. J Cataract Refract Surg. 2004;30:1727-1731.
31. Kung YH, Wu TT, Hong MC, Sheu SJ. Intravitreal tissue plasminogen activator and pneumatic displacement of submacular hemorrhage. J Ocul Pharmacol Ther. 2010;26:469-474.
32. Chen CY, Hooper C, Chiu D, Chamberlain M, Karia N, Heriot WJ. Management of submacular hemorrhage with intravitreal injection of tissue plasminogen activator and expansile gas. Retina. 2007;27:321-328.
33. Holland D, Wiechens B. Intravitreal r-TPA and gas injection in traumatic submacular hemorrhage. Ophthalmologica. 2003; 218:64-69.
34. Gerometta R, Spiga M-G, Borrás T, Candia OA. Treatment of sheep steroid-induced ocular hypertension with a glucocorticoid-inducible MMP1 gene therapy virus. Invest Ophthalmol Vis Sci. 2010;51:3042-3048.
35. Krohne TU, Liu Z, Holz FG, Meyer CH. Intraocular pharmacokinetics of ranibizumab following a single intravitreal injection in humans. Am J Ophthalmol. 2012;154:682-686. e2.
36. Xu L, Lu T, Tuomi L, et al. Pharmacokinetics of ranibizumab in patients with neovascular age-related macular degeneration: a population approach. Invest Ophthalmol Vis Sci. 2013;54: 1616-1624.
37. Kim MH, Koo TH, Sah WJ, Chung SM. Treatment of total hyphema with relatively low-dose tissue plasminogen activator. Ophthalmic Surg Lasers. 1998;29:762-766.
38. Chen SN, Yang TC, Ho CL, Kuo YH, Yip Y, Chao AN. Retinal toxicity of intravitreal tissue plasminogen activator: case report and literature review. Ophthalmology. 2003;110:704-708.
39. Oh H-S, Kwon OW, Chung I, et al. Retinal toxicity of commercial tissue plasminogen activator is mediated by the induction of nitric oxide in the mouse retinal primary cells. Curr Eye Res. 2005;30:291-297.
40. Hrach CJ, Johnson MW, Hassan AS, Lei B, Sieving PA, Elner VM. Retinal toxicity of commercial intravitreal tissue plasminogen activator solution in cat eyes. Arch Ophthalmol. 2000;118: 659-663.
41. Chen J, Wollman Y, Chernichovsky T, Iaina A, Sofer M, Matzkin H. Effect of oral administration of high-dose nitric oxide donor L-arginine in men with organic erectile dysfunction: results of a double-blind, randomized, placebo-controlled study. BJU Int. 1999;83:269-273.
42. Wun T-C. Plasminogen activation: biochemistry, physiology, and therapeutics. Crit Rev Biotechnol. 1988;8:131-148.
43. Davydov L, Cheng JW. Tenecteplase: a review. Clin Ther. 2001; 23:982-997.
44. Hu K, Yang J, Tanaka S, Gonias SL, Mars WM, Liu Y. Tissue-type plasminogen activator acts as a cytokine that triggers intracellular signal transduction and induces matrix metalloproteinase-9 gene expression. J Biol Chem. 2006;281:2120-2127.
45. Wang X, Lee SR, Arai K, Tsuji K, Rebeck GW, Lo EH. Lipoprotein receptor-mediated induction of matrix metalloproteinase by tissue plasminogen activator. Nat Med. 2003; 9:1313-1317.
46. Lijnen HR. Elements of the fibrinolytic system. Ann N Y Acad Sci. 2001;936:226-236.
47. Bachmann B, Birke M, Kook D, Eichhorn M, Lutjen-Drecoll E. Ultrastructural and biochemical evaluation of the porcine anterior chamber perfusion model. Invest Ophthalmol Vis Sci. 2006;47:2011-2020.
48. Ning M, Furie KL, Koroshetz WJ, et al. Association between tPA therapy and raised early matrix metalloproteinase-9 in acute stroke. Neurology. 2006;66:1550-1555.
49. Tsuji K, Aoki T, Tejima E, et al. Tissue plasminogen activator promotes matrix metalloproteinase-9 upregulation after focal cerebral ischemia. Stroke. 2005;36:1954-1959.
50. Wang X, Lee S-R, Arai K, et al. Lipoprotein receptor-mediated induction of matrix metalloproteinase by tissue plasminogen activator. Nat Med. 2003;9:1313-1317.
51. Ning M, Furie K, Koroshetz W, et al. Association between tPA therapy and raised early matrix metalloproteinase-9 in acute stroke. Neurology. 2006;66:1550-1555.
52. Tsuji K, Aoki T, Tejima E, et al. Tissue plasminogen activator promotes matrix metalloproteinase-9 upregulation after focal cerebral ischemia. Stroke. 2005;36:1954-1959.
53. Vincenti MP, White LA, Schroen DJ, Benbow U, Brinckerhoff CE. Regulating expression of the gene for matrix metalloproteinase-1 (collagenase): mechanisms that control enzyme activity, transcription, and mRNA stability. Crit Rev Eukaryot Gene Expr. 1996;6:391-411.
54. Nagase H, Woessner JF. Matrix metalloproteinases. J Biol Chem. 1999;274:21491-21494.
55. Robertson JV, Siwakoti A, West-Mays JA. Altered expression of transforming growth factor beta 1 and matrix metalloproteinase-9 results in elevated intraocular pressure in mice. Mol Vis. 2013;19:684-695.